Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC).
Philip Jordan Gold
Research Funding - Novartis
David A. Smith
No relevant relationships to disclose
Desiree Iriarte
No relevant relationships to disclose
Barry Boatman
No relevant relationships to disclose
Henry G. Kaplan
No relevant relationships to disclose